Detection of MAP1A expression in prostate cancer and its clinical characteristics

doi:10.3969/j.issn.1006-7795.2019.01.012

Abstract

Abstract: Objective To investigate the expression of MAP1A in prostate cancer and its relationship with clinical features. Methods The expression of MAP1A at the protein level in human prostate cancer and non-cancerous prostate tissue was detected with immunohistochemistry, and it was further validated with quantitative real-time polymerase chain reaction (RT-qPCR) at the mRNA level. Subsequently, the association of MAP1A expression with the clinical characteristics of the patients with prostate cancer was statistically analyzed with the Cancer Genome Atlas (TCGA) database. Results Immunohistochemistry stains showed that the protein expression of MAP1A was significantly decreased in prostate cancer tissues compared with adjacent normal tissues[immunoreactive score (IRS):Prostate cancer tissue=4.08±1.58,Tumor-adjacent normal tissue=4.91±1.46,P<0.001]. The positive expression rates of MAP1A in PCa tissue samples and adjacent normal tissue samples were 58.6% and 82.7%, respectively, indicating a statistically significant difference (χ²=12.225,P=0.001). MAP1A mRNA expression was detected with quantitative real-time PCR and it was significantly lower in prostate cancer than in normal prostate tissue (P=0.019). Analysis of TCGA data suggested, that the expression of MAP1A is significantly different in the tumor tissues with different clinical characteristics, such as Gleason score (P<0.001), clinical pathological stage (P=0.009), metastasis (P=0.008), and overall survival rate (P=0.049). Conclusion MAP1A is down-regulated in prostate cancer and is associated with the staging of tumor tissue. The later stage of tumor tissue, the lower the expression of MAP1A, suggesting that MAP1A is related to the development and progression of prostate cancer.

Key words: prostate cancer(PCa), microtubule associated protein 1A(MAP1A), clinical characteristics

CLC Number:

R737.25

Wang Wei, Su Jiaming, Yuan Dongbo, Zhang Wei, Chen Weihong, Sun Zhaolin, Zhu Jianguo. Detection of MAP1A expression in prostate cancer and its clinical characteristics[J]. Journal of Capital Medical University, 2019, 40(1): 65-71.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2019.01.012

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2019/V40/I1/65

References

[1] Wong M C, Goggins W B, Wang H H, et al. Global incidence and mortality for prostate cancer:analysis of temporal patterns and trends in 36 countries[J]. Eur Urol, 2016, 70(5):862-874.
[2] Siegel R L, Miller K D, Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1):7-30.
[3] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
[4] Chen W, Zheng R, Baade P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
[5] Gerhauser C, Favero F, Risch T, et al. Molecular evolution of early-onset prostate cancer identifies molecular risk markers and clinical trajectories[J].Cancer Cell,2018,34(6):996-1011.
[6] Wedge D C, Gundem G, Mitchell T, et al. Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets[J].Nat Genet, 2018,50(5):682-692.
[7] Cucchiara V, Cooperberg M R, Dall'Era M, et al. Genomic markers in prostate cancer decision making[J].Eur Urol,2018,73(4):572-582.
[8] Halpain S, Dehmelt L. The MAP1 family ofmicrotubule-associated proteins[J]. Genome Biol, 2006, 7(6):224.
[9] Chu J, Li N,Gai W. Identification of genes that predict the biochemical recurrence of prostate cancer[J]. Oncol Lett, 2018, 16(3):3347-3452.
[10] Canes D. Prostate cancer:Determining optimal therapy of early-stage disease remainscomplicated[J]. Nat Rev Urol, 2016, 13(12):703-704.
[11] McPhail S, Johnson S, Greenberg D, et al. Stage at diagnosis and early mortality from cancer in England[J]. Br J Cancer, 2015, 112:S108-S115.
[12] 马悦,陈弋生. 前列腺癌精准诊断的新进展[J]. 中华男科学杂志, 2016, 22(11):1030-1033.
[13] 张振奇,刘桂丽,夏小彬,等.血清PHI和尿PCA3联合检测评分对PSA灰区前列腺癌诊断价值探讨[J].中华肿瘤防治杂志,2018,25(5):329-333.
[14] 赖亚明,韩斌,吴斌.Gleason评分对前列腺癌转归预测意义[J].中华肿瘤防治杂志,2018,25(13):951-955.
[15] Thompson I M,Pauler D K,Goodman P J,et al.Prevalence of prostate cancer among men with a prostate specific antigen level[16] Mistry K,cable G. Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma[J].J Am Board Fam Pract,2003,16(2):95-101.
[17] 年新文,任善成,许传亮. 前列腺癌早期诊断标志物的研究进展[J]. 临床泌尿外科杂志,2016,31(9):852-855.
[18] Kazzazi A, Momtahen S, Bruhn A, et al. New findinfs in localized and advanced prostate cancer:AUA 2011 review[J]. Can J Urol, 2011,18(3):5683-5688.
[19] Litwin M S, Tan H J. The diagnosis and treatment of prostate cancer:a review[J]. JAMA, 2017, 317(24):2532-2542.
[20] Helgstrand J T, Roder M A, Klemann N, et al. Diagnostic characteristics of lethal prostate cancer[J]. Eur J Cancer, 2017,84:18-26.
[21] Li S, Ma Y, Xie C, et al. EphA6 promotes angiogenesis and prostate cancer metastasis and is associated with human prostate cancer progression[J]. Oncotarget, 2015, 6(26):22587-22597.
[22] Kendel F, Helbig L, Neumann K, et al. Patients' perceptions of mortality risk for localized prostate cancer vary markedly depending on their treatment strategy[J]. Int J Cancer., 2016, 139(4):749-753.
[23] 冯思坛,施鑫. 微管相关蛋白与肿瘤关系的研究进展[N]. 医学研究生学报, 2013,26(8):878-881.
[24] Fink J K, Jones S M, Esposito C,et al. Human microtubule-associated protein 1a (MAP1A) gene:genomic organization, cDNA sequence, and developmental-and tissue-specific expression[J]. Genomics, 1996, 35(3):577-585.
[25] Liu Y, Lee J W, Ackerman S L,et al. Mutations in the microtubule-associated protein 1A (Map1a) gene cause Purkinje cell degeneration[J].J Neurosci,2015,35(11):4587-4598.
[26] Meyer M A. Highly expressed genes in human high grade gliomas:immunohistochemical analysis of data from the human protein atlas[J]. Neurol Int, 2014, 6(2):5348.
[27] Knutson T P, Daniel A R, Fan D,et al. Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression[J]. Breast Cancer Res, 2012, 14(3):R95.
[28] Jiang X, Zhong W, Huang H,et al. Autophagy defects suggested by low levels of autophagy activator MAP1S and high levels of autophagy inhibitor LRPPRC predict poor prognosis of prostate cancer patients[J]. Mol Carcinog, 2015, 54(10):1194-1204.